In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

QRxPharma Limited

http://www.qrxpharma.com/

Latest From QRxPharma Limited

Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids

The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.

Turning the Page on Zohydro? New Formulations, New Division Leadership Should Help FDA Move Forward in Opioids

The long-time head of FDA’s pain drug review group, Bob Rappaport, has retired after 20 years at FDA. The new acting Division Director is Sharon Hertz – suggesting continuity in the substance of reviews, but perhaps a symbolic change in moving beyond the controversy over Zohydro.

BioPharmaceutical Regulation

Execs On The Move, July-August 2014

Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.

BioPharmaceutical Medical Device

REJECTED: Strike 3 for QRxPharma's opioids combo MoxDuo

The FDA for the third time has rejected QRxPharma's application for its morphine/oxycodone combination drug MoxDuo – news that sent shares of the firm tumbling as low as 15.4% on 27 May.

Neurology Respiratory
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
UsernamePublicRestriction

Register